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Abstract
Cell transplantation is considered a promising therapeutic approach in several pathologies but still needs
innovative and non-invasive imaging technologies to be validated. The use of mesenchymal stem cells (MSCs)
attracts major interest in clinical transplantation thanks to their regenerative properties, low immunogenicity
and ability to regulate immune responses. In several animal models, MSCs are used in co-transplantation with
pancreatic islets (PIs) for the treatment of type I diabetes, supporting graft survival and prolonging normal
glycaemia levels. In this study we investigated the homing of systemically administered MSCs in a rat model of
pancreatic portal vein transplantation. MSCs labelled with quantum dots (Qdots) were systemically injected by
tail vein and monitored by optical fluorescence imaging. The fluorescence signal of the liver in animals co-
transplanted with MSCs and PIs was significantly higher than in control animals in which MSCs alone were
transplanted. By using magnetic labelling of PIs, the homing of PIs into liver was independently confirmed.
These results demonstrate that MSCs injected in peripheral blood vessels preferentially accumulate into liver
when PIs are transplanted in the same organ. Moreover, we prove that bimodal MRI-fluorescence imaging
allows specific monitoring of the fate of two types of cells.
Key words: fluorescence imaging; magnetic resonance imaging; mesenchymal stem cells; pancreatic islets;
quantum dots; transplantation.
Introduction
Cell transplantation is considered a promising therapeutic
approach in several pathologies including neurological (De
Feo et al. 2012), cancerous (Aly, 2012), musculoskeletal (Nie
et al. 2012), and metabolic diseases (Longoni et al. 2010).
Among cell-based therapies, stem cells (SCs) evoke great
interest due to their ability to self-renew and to differenti-
ate into multiple cell lineages (Wei et al. 2013). To be used
safely in clinical settings, SCs should demonstrate genomic
stability, be readily harvested and/or expanded and, above
all, not induce teratomas (Sohni & Verfaillie, 2013). Embry-
onic stem cells (ESCs), which can be derived from blastocyst,
are pluripotent cells displaying genomic stability (Evans &
Kaufman, 1981; Yoon et al. 2014). Beyond the ethical con-
cerns due to their origin, ESCs can induce teratoma forma-
tion in vivo (Przyborski, 2005; Blum & Benvenisty, 2008) and
may elicit tissue rejection following transplantation in
patients. The advent of induced pluripotent stem cell, dis-
covered in 2006 by Takahashi and Gurdon (Gurdon, 2006;
Takahashi & Yamanaka, 2006), opened new perspectives for
SC therapy. These cells can indeed be obtained by repro-
gramming differentiated adult cells, overcoming limitations
due to ethical concerns, and can be differentiated in any
lineages. However, to be considered clinically safe, their
genomic stability still needs to be established (Ullah et al.
2015).
Mesenchymal stem cells (MSCs), which are adult stem cells
of mesodermal origin, are free from ethical concerns, thus
becoming a promising candidate for cell therapies (Horwitz
et al. 2005). Along with multi-potency and self-renewal,
MSCs lack the co-stimulatory molecules of the class II major
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histocompatibility complex (MHC II); moreover, they exhibit
immunosuppressive properties; their overall immunological
features and low immunogenicity makes them an attractive
tool for the development of transplantation approaches
(Patel et al. 2008). The use of MSCs in association with pan-
creatic islets (PIs) in animal transplants has been largely
investigated for the treatment of type I diabetes (Ricordi &
Strom, 2004; Domınguez-Bendala et al. 2012), a pathology
characterized by the irreversible autoimmune destruction
of pancreatic beta cells (Sakata et al. 2010). Islet transplan-
tation in the portal vein of patients affected by type I dia-
betes combines minimally invasive surgery with low
incidence of peri-operative risks (Weimar et al. 1999) while
improving glycaemic control and prospective insulin inde-
pendence (Sutherland et al. 1993; Bretzel et al. 1995;
Hogan et al. 2008). We recently reported that co-transplan-
tation of MSCs and PIs helps to prolong normal glycaemic
levels in an experimental model of chemically induced dia-
betes in rats (Longoni et al. 2010). The effect of the intra-
venous administration of MSCs was assessed in both an
allogeneic and a syngeneic model. PIs transplanted in the
portal vein engrafted into the liver as demonstrated by
in vivo imaging studies (Marzola et al. 2009; Arifin & Bulte,
2011). Several papers showed that when MSCs are injected
systemically they preferentially distribute to a wide variety
of organs, i.e. spleen and lungs (with cell entrapment trig-
gered by MSCs dimensions) (Vittorio et al. 2011), resulting
in a loss of therapeutic efficacy. Therefore additional inves-
tigations of the stem cell homing are required to improve
the efficacy of cell therapies. Non-invasive imaging tech-
niques such as magnetic resonance imaging (MRI), optical
imaging (OI) and positron emission tomography (PET) are
widely used to visualize cells in vivo in intact organisms
after labelling cells with magnetic (Sykova & Jendelova,
2007; Oishi et al. 2013), fluorescent (Yukawa et al. 2012) or
radioactive (Wu et al. 2013) probes, prior to their transplan-
tation. We reported that PIs can be labelled with superpara-
magnetic iron oxide particles (SPIOs) and visualized in the
liver of the recipient subject by MRI with high sensitivity
(Marzola et al. 2009; Arifin & Bulte, 2011). Furthermore,
several articles have shown that SCs can also be labelled
with superparamagnetic particles without relevant cytotoxic
effects and detected with high sensitivity in vivo by MRI. In
the present study, MSCs and PIs were co-transplanted
within the same experimental procedure and visualized
with two different imaging techniques. PIs are easily detect-
able using SPIO labelling and MRI as demonstrated in our
previous work (Marzola et al. 2009; Longoni et al. 2010). To
image MSCs we decided to use as a fluorescent probe quan-
tum dots (Qdots), which are specifically designed for cell
labelling. Qdots emitting in the near infrared range, i.e.
inside the transparency window of living tissue, were cho-
sen. The attenuation of light in biological tissues depends
on the combined effect of light absorption and scattering,
well expressed by the inverse exponential power law
(Beer–Lamberts Law). Increasing the depth of the light
source, the signal highly decreases, so due to the thickness
of rat tissues, we were forced to work ex vivo by acquiring
fluorescence images of excised organs rather than working
in vivo. The presence of the PI into the liver was demon-
strated by our previous studies (Marzola et al. 2009;
Longoni et al. 2010) and confirmed by this study. Our data
clearly demonstrate that MSCs, injected immediately after
PI transplantation during the same experimental procedure,
were driven into the liver to a greater extent compared
with control animal, in which MSCs alone were adminis-
tered. The novelty of our approach provides the proof of
concept that bimodal labelling of two different kind of cells
and the use of a bimodal imaging modality can be used to




Inbred male Lewis (L) (n = 36) and Wistar Furth (WF) (n = 20) rats,
weighing 275–300 g, were purchased from Charles River Laborato-
ries (Italy). The animals, fed on standard rodent chow (Rieper, Italy)
and water ad libitum, were kept in a 12 h light/dark cycle. In our
experimental model, WF rats were used as donors and L rats as
recipients of PIs. All experimental procedures were carried out with
the approval of the Ethical Committee for Animal Experimentation
of the University of Pisa.
MSC isolation and culture
MSCs and bone marrow cells were collected from both tibias and
femurs of L rats following Dobson’s procedure (Dobson et al. 1999).
Total nucleated cells were cultured in Dulbecco’s modified culture
medium (DMEM; Sigma-Aldrich, Italy) supplemented with 10% fetal
bovine serum (FBS; Eurobio, Italy), 1% L-glutamine (Sigma-Aldrich),
penicillin (50 lg mL1; Eurobio), streptomycin (50 lg mL1; Euro-
bio), amphotericin B (0.2 lg mL1; Sigma-Aldrich), and incubated
at 37 °C in a fully humidified atmosphere containing 95% air and
5% carbon dioxide. After 7 days, half of the culture medium was
changed. On reaching confluence, the adherent cells were
detached by 0.05% trypsin and 0.02% EDTA for 5–10 min at 37 °C,
harvested and washed with Hanks’ balanced salt solution (HBSS)
and 10% FBS and finally re-suspended in complete medium (pri-
mary culture, P0). Cells were re-seeded at 104 cells cm2 in 100-mm
dishes (P1) for both in vitro differentiation assessment and subse-
quent cellular expansion, which was achieved by successive cycles of
trypsinization and re-seeding. The frequency of colony forming
units-fibroblasts (CFU-F) was measured using the method of Castro-
Malaspina (Gay et al. 1980). Visible colonies with 50 or more cells
(the conventional value for defining a colony) were counted and
referred to 106 plated cells (no. of CFU-F/106 TNC).
In vitro experiments
MSCs were labelled with Qdots (Qtracker 800 kit cell labelling;
InvitrogenTM Milan, Italy) following the datasheet instructions.
Briefly, 10 nmol Qdots were added to MSCs in T75 flask. After 1 h,
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the adherent cells were detached by 0.05% trypsin/EDTA (Life
Technology, Italy), counted, centrifuged at 150 g, washed three
times in phosphate buffered saline (PBS) and re-suspended in
300 lL of DMEM without FBS. After labelling, the fluorescence sig-
nal of MSCs was measured in vitro. Different amounts of labelled
cells (range 50–105 cells) were suspended in non-fluorescent wells
and acquired by OI in the fluorescence modality using the same
experimental setup as in the excised organs acquisition protocol
(Fig. 1C).
Pancreatic islets isolation, culture and labelling
Pancreatic islets were isolated from WF rats (275–300 g) by collage-
nase P (Roche Diagnostics, Italy) perfusion and purified by
continuous-density Ficoll gradient as previously described (Longoni
et al. 2010). Briefly, the pancreas was distended by bile duct injec-
tion of 15 mL of 4 °C-cold collagenase P (1 mg mL1; Roche Diag-
nostics) diluted in HEPES-buffered HBSS (Sigma-Aldrich), and then
excised and minced. PIs were digested at 37 °C for 20 min under
constant stirring. Islets were separated from exocrine tissue by cen-
trifugation on a Histopaque (Sigma-Aldrich) discontinuous gradient,
removed from the interface of the layers, washed in HBSS and
finally resuspended in 10 mL of RPMI (Eurobio) supplemented with
10% fetal calf serum (Eurobio), 1% L-glutamine, 10 mM glucose
(Sigma-Aldrich), penicillin (50 U mL1, Eurobio), streptomycin
(50 lg mL1; Eurobio), amphotericin B (0.2 lg mL1; Eurobio) and
1% HEPES buffer (Sigma-Aldrich) in a free-floating culture flask. PIs
were handpicked under an inverted microscope under sterile condi-







Fig. 1 Differentiation of MSCs. (A) Osteocytes, with visible deposits of hydroxyapatite stained intensely red with of Alizarin S, (B) orange–red-
stained lipid vacuoles of the cytoplasm of MSCs treated with adipogenic medium with Oil Red-O. (C) Fluorescence images of nonfluorescent wells
containing varying amounts of MSCs labeled with Qdots 800: a) control – no cells, b) 50 cells, c) 100 cells, d) 500 cells, e) 1000 cells, f) 2.5 9 103
cells, g) 5 9 103 cells, h) 10 9 103 cells, i) 20 9 103 cells, j) 40 9 103 cells, k) 80 9 103 cells, l) 100 9 103 cells. (D) Signal intensity of fluores-
cence images of nonfluorescent wells containing varying amounts of Qdots-labeled (blue squares) or unlabeled (red squares) cells. Acquisition
modality: fluorescence with filters ex/em = Cy5.5 (615–665 nm)/ICG (810–875 nm).
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For each graft, the total islet mass was expressed as the 150-lm-dia-
meter islet equivalent number, calculated on the basis of volumetric
assumptions. PIs were incubated at 37 °C (95% air and 5% CO2), for
1–2 days before transplantation. The amount of PIs needed to
transplant in n = 2 recipients was labelled with SPIOs (Endorem,
Guerbet, France) according to previously published methods (Mar-
zola et al. 2009; Longoni et al. 2010).
Transplantation of PIs and MSCs
The effect of MSC intravenous administration was assessed in an
allogeneic graft using Wistar Furth rats as donors and Lewis rats as
recipients of PIs. Lewis rats were divided into four groups. Group 1
(n = 6) received saline intravenously (i.v.). Group 2 (n = 6) received
5 9 105 unlabelled MSCs i.v. Group 3 received 5 9 105 MSCs
labelled with Qdots i.v. (n = 12; n = 6 rats were sacrificed 5 days
and n = 6 rats 10 days after i.v. injection). Group 4 was divided in
two subgroups: in the first one (4a) the rats received 700 IE islets in
a portal vein and 5 9 105 MSCs labelled with Qdots i.v. (n = 12;
n = 6 were sacrificed 5 days and n = 6 rats 10 days after i.v. injec-
tion). Animals belonging to the other subgroup (4b) (n = 2)
received 700 IE islets labelled with SPIOs in a portal vein and
5 9 105 MSCs labelled with Qdots i.v., and were sacrified 10 days
after transplantation of PIs and i.v. injection of MSCs.
Lewis rats (230–250 g) were anaesthetized (Zoletil 100: tiletam-
inw 90 mg kg1 and zolazepam 10 mg kg1, Virbac s.r.l., by
intraperitoneal injection) and the portal vein was exposed through
a midline incision parallel to the spine. PIs suspended in 200 lL of
PBS solution were injected and re-flushed two to three times into
the portal vein. An amount of 5 9 105 MSCs labelled with QDots
(or the same amount of unlabelled MSCs) were transplanted in L
rats by i.v. injection in the tail vein. After 5 or 10 days, the animals
were sacrificed and perfused with PBS. The following organs were
excised: liver, lungs, spleen, kidneys and pancreas.
Imaging in vivo and ex vivo experiments
The rats of the subgroup 4b were anaesthetized (0.5–1% isofluo-
rane) and placed into a 7.2-cm i.d. transmitter-receiver birdcage coil.
MRI in vivo acquisitions were performed 10 days after transplanta-
tion using a 4.7 T 33-cm bore horizontal magnet (Oxford Ltd.,
Oxford, UK). Acquisition protocol was described in Marzola et al.
(2009).
Fluorescence images were acquired using a VivoVision Systems,
IVIS 200 Series, for small laboratory animals (Caliper, Alameda,
CA, USA). The system is made of a camera sensor back-thinned,
back-illuminated, grade CCD 1 (2.7 9 2.7 cm, 90 °C), with a mini-
mal image pixel resolution of 20 lm (pixel dimension 13.5 lm,
imaging pixels 2048 9 2048), quantum efficiency > 85% between
500 and 700 nm, and > 30% between 400 and 900 nm. For the
experiments we used a fluorescent modality with Cy5.5 (615–
665 nm) excitation filter and ICG (810–875 nm) emission filter.
Images were acquired with binning factor = 8, field of
view = 12.8 cm, exposure time = 1 s, opening of diaphragm (f/
stop) = 2.
Ex vivo fluorescence images of excised organs from all the experi-
mental groups were acquired and analysed using LIVING IMAGE 4.1
software (Caliper). According to Yukawa et al. (2012) the quantifi-
cation of fluorescence emission of different excised organs was per-
formed by considering the parameter RFI (ratio of fluorescence
intensity), defined as follows: RFI = (fluorescence intensity of the
organ)/(total fluorescence intensity of the five excised organs of the
same animal: liver, kidneys, lungs, spleen, pancreas). Data analysis
and statistics were carried out using routines written in MATLAB 7.1
(The MathWorks Inc., USA). A t-test analysis was performed with a
significance level of P ≤ 0.05.
Results
Characterization of MSCs in vitro
Rat bone marrow-derived MSCs were purified by plastic
adherence. After the fifth passage, the cells grew exponen-
tially, requiring weekly passages. MSCs treated with osteo-
genic medium formed small deposits of hydroxyapatite
intensely red stained with Alizarin S (Fig. 1A). Treatment
with adipogenic medium differentiated MSCs towards adi-
pogenic lineages with Oil Red-O staining (Fig. 1B). Cytofluo-
rimetric analysis showed the existence of a homogeneous
population of adherent cells (after four to five passages),
positive for CD90, CD44, CD54, CD73 and CD106. There was
no significant contamination of haematopoietic cells, as
flow cytometry was negative for markers of haematopoietic
lineage, including CD11b and CD45 (data not shown).
The MSC labelling was observed in vitro by OI in fluores-
cence modality in order to assess the sensitivity of the tech-
nique. Images of wells containing different amounts of
labelled or unlabelled cells are shown in Fig. 1C. The depen-
dence of fluorescence signal intensity on the cell number is
shown in Fig. 1D for labelled and unlabelled cells. A good
correlation was found between signal intensity of wells
containing labelled cells and the number of cells itself
(r2 = 0.84).
A slight decrease of the total flux at the highest number
of cells was observed, probably due to the optical thickness
of the cells. The fluorescence signal acquired in non-
fluorescent wells containing pure DMEM or unlabelled cells
was significantly lower than the signal acquired in wells
containing labelled cells (Fig. 1). Even at the lowest number
of cells investigated (n = 50), the fluorescence signal (1.14
 0.03 9 108 photon s1) was substantially higher com-
pared with pure DMEM (2.47  0.33 9 107 photon s1) or
to 50 unlabelled cells (2.20  0.42 9 107 photon s1). This
result indicates an in vitro detection limit of about 50 cells.
Imaging in vivo and ex vivo experiments
The rats of subgroup 4b were imaged by MRI to monitor
the presence of PIs labelled with SPIOs into the liver (Mar-
zola et al. 2009; Longoni et al. 2010). Figure 2 shows a rep-
resentative in vivo MR image of rat transplanted with PIs
labelled with SPIOs 10 days after the PI transplantation. In
vivo MRI acquisitions showed the image of the animal with
PIs unlabelled (Fig. 2A) with respect to the image of hepatic
parenchyma, with several dark spots corresponding to
labelled PIs (Fig. 2B), confirming data described in Marzola
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et al. (2009). No differences were found in the fluorescent
light signal coming from the explanted liver between the
animal of subgroup 4b and the animal of subgroup 4a, sug-
gesting that no significative absorption of fluorescent emis-
sion can be attributed to the opacity of the MRI contrast
agent.
The presence of labelled MSCs in different organs was
studied ex vivo by fluorescence imaging.
Figure 3 shows fluorescence images of excised organs of
representative rats sacrificed 5 (Fig. 3A) and 10 (Fig. 3B)
days after injection with unlabelled MSCs (group 2),
labelled MSCs (group 3), labelled MSCs plus transplantation
of PIs (group 4). Qualitatively, the fluorescence signal emit-
ted from organs of animals belonging to group 4 (MSCs
and PIs) is higher than in the other experimental groups,
suggesting longer duration of MSCs in the body. Organs
excised from animals belonging to group 1 (saline) had a
fluorescence emission comparable to organs excised from
animals belonging to group 2 (images not shown). Data
were then quantitatively analysed. To assess the possible
effect of co-transplantation of PIs on MSC homing; data
from animals belonging to experimental groups 3 and 4 (la-
belled MSCs) were compared by considering the RFI index
previously defined (see Fig. 3C). Five days after transplanta-
tion, the fluorescence emission in liver of animals belonging
to group 4 was significantly higher than in group 3, indicat-
ing that transplantation of PIs promotes homing of MSCs in
the liver. The organs of group 4 were representative of all
organs of subgroups 4a and 4b. The difference is not statis-
tically significant in other organs (except lungs). For exam-
ple, although the kidney fluorescence in group 4 is
qualitatively much higher than in group 3, the difference is
not statistically significant when data are analysed using
the RFI index.
Discussion
In recent years, research in cell therapy for regenerative
medicine has considered MSCs with increasing interest.
MSCs have been largely applied in tissue regeneration mod-
els, in transplantation and for the treatment of several
degenerative pathologies. Data derived from these studies
have shown that MSCs may be a safe and realistic therapy
for clinical use. Strictly related to the above-mentioned
applications of MSCs is the need to monitor the fate of
transplanted cells, and indeed several recently published
papers have investigated their homing and biodistribution
in animal models. Moreover, as many applications of MSCs
have been performed in association with other cell types, it
is very important to develop bimodal imaging methods to
make it possible to follow the fate of different kinds of
transplanted cells. Fluorescent Qdots were used here to
label stem cells and they are widely used in preclinical stud-
ies, but their chemical composition, in particular the pres-
ence of cadmium in their core, prevents clinical application.
For clinical use, nanoparticles with different chemical com-
position could be used in the future, but the optical thick-
ness of the human tissue could represent a very important
issue for fluorescence imaging.
In the present work, we investigated the homing of MSCs
in an animal model of PI transplantation by bimodal imag-
ing techniques. MSCs were labelled using fluorescent
probes, whereas PIs were labelled with magnetic nanoparti-
cles. Optical and MR imaging allowed detection of cells
homing in different organs. When only MSCs are trans-
planted, the fluorescence signal emitted by excised organs,
5 or 10 days after injection of labelled MSCs, is similar to
the baseline level (i.e. approximatively equal to the fluores-
cence emitted in the animal receiving unlabelled MSCs;
compare groups 2 and 3 in Fig. 3A,B). This finding indicates
that MSCs are cleared from the body within these time
intervals. In contrast, fluorescence emission in the liver in
group 4, in which labelled MSCs were co-transplanted with
PIs, was significantly higher than in group 3, in which only
labelled MSCs were transplanted. No statistically significant
difference was detected in other organs, except lungs. This
result, together with the good linear correlation observed
in vitro between the number of labelled MSCs and the fluo-
rescence signal (see Fig. 1), demonstrates that MSCs, when
co-transplanted with PIs, show preferential homing into the
liver. Ten days after transplantation, such preferential hom-
ing is no longer detectable.
A B
Fig. 2 MRI images of a representative animal
with PIs unlabeled (A) and an animal with PIs
labeled with superparamagnetic iron oxide
particles (SPIOs) and MSCs labeled with Qdots
(B).
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The high number of MSCs in liver observed when animals
are transplanted with PIs may be correlated with inflamma-
tion and possible graft rejection of allogeneic islets. Indeed,
it is well known that during an inflammation process (or tis-
sue damage) MSCs are recruited by means of chemokines to
the site of inflammation to suppress immune response and
promote regeneration (Spaggiari & Moretta, 2013). The
immunomodulatory effect of the MSCs is demonstrated in
many in vitro studies showing that MSCs suppress T-cell pro-
liferation, indicating immunosuppressive properties and
reduced inflammation (Inoue et al. 2006; Le Blanc & Ring-
den, 2007).
Several papers have examined the immunomodulatory
effect of MSCs in the transplantation of PIs and in a previ-
ous study of this project, our group has also analysed
(Longoni et al. 2010) the role of interferon gamma and
granulocyte colony stimulating factor blood levels after PI
and MSC inoculation; however, to the best of our knowl-
edge the homing of MSCs has not been investigated in this
model. Over the last 10 years, a number of studies have
investigated in vivo the homing of SCs in a wide variety of
other experimental diseases (Sohni & Verfaillie, 2013; Davey
et al. 2014; Kavanagh et al. 2014; Ying et al. 2014). Most
papers were based on MRI, but attention has recently been
devoted to optical techniques in bioluminescence or fluo-
rescence modality (Yukawa et al. 2012). Although many
attempts have been made to reveal the MSC fate for surgi-
cal approaches within PI transplants, this topic needs to be
analysed further. We transplanted PIs and injected MSCs in




Fig. 3 Fluorescence images of excised organs of representative rats injected with MSCs and sacrificed 5 (A) and 10 (B) days after PIs transplanta-
tion. Group 2 rat injected i.v. with unlabeled MSCs; group 3 rat injected i.v. with labeled MSCs; group 4 rats injected i.v. with labeled MSCs and
PIs. Acquisition modality: fluorescence with filters ex/em = Cy5.5 (615–665 nm)/ ICG (810–875 nm). Organs are shown here with different degrees
of magnification. (C) Average signal emitted in different organs (RFI), n = 6 for each groups. Data are reported as mean  SD over the different
experimental groups. T-test analysis was performed, and statistical differences (P ≤ 0.05) were indicated (*).
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imaging approach to differentially monitor cellular homing.
We used a bimodal acquisition system: fluorescence detec-
tion by OI to explore the homing of MSCs and MRI to inves-
tigate the fate of PIs. A limit of this approach is that OI
suffers from relatively small penetration depth in living tis-
sues that prevented us from working in vivo. This paper rep-
resents proof of concept that joint application of MRI and
OI can allow simultaneous monitoring of the fate of trans-
planted cells.
Conclusions
We investigated the homing of MSCs labelled with QDots
and i.v. injected in an animal model of PI transplantation
(Marzola et al. 2009; Longoni et al. 2010). When unlabelled
MSCs were injected, the fluorescence signal of the liver was
not different from that of the controls (in which saline or
unlabelled MSCs were injected). When MSCs were injected
immediately after PI transplantation, the PIs were indepen-
dently monitored with MRI and persisted in the liver for
10 days after the transplantation; the fluorescence signal of
the liver was significantly stronger than in the control,
showing that MSCs preferentially accumulate in the liver.
This paper demonstrates that bimodal MRI and fluores-
cence imaging allows differential monitoring of the fate of
two types of transplanted cells. Moreover, it shows that i.v.
injected MSCs accumulate in liver when PIs have been trans-
planted in the same organ.
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